Malabre Richard C

SVP, Chief Accounting OfficerAkebia Therapeutics, Inc. (AKBA) · full profile →Form 4 · filed Feb 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$69K
Net Open-Market Flow
-$69K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2026Sell(S)13K$1.39$19K299K
Feb 2, 2026Sell(S)36K$1.39$50K313K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002007730-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly: